
1. sci rep. 2017 apr 18;7:46482. doi: 10.1038/srep46482.

rational development protective p. vivax vaccine evaluated transgenic
rodent parasite challenge models.

salman am(1)(2), montoya-díaz e(1), west h(1), lall a(1), atcheson e(1),
lopez-camacho c(1), ramesar j(2), bauza k(1), collins ka(1), brod f(1), reis
f(3), pappas l(1), gonzález-cerón l(4), janse cj(2), hill avs(1), khan sm(2),
reyes-sandoval a(1).

author information: 
(1)the jenner institute, nuffield department medicine, university oxford,
the henry wellcome building molecular physiology, roosevelt drive, oxford,
ox3 7bn, uk.
(2)leiden malaria research group, department parasitology, center of
infectious diseases, leiden university medical center, (lumc, l4-q), albinusdreef
2, 2333 za leiden, netherlands.
(3)universidade federal de minas gerais, belo horizonte - mg - brasil.
(4)centro regional de investigación en salud pública, instituto nacional de salud
pública, 4ta avenida norte calle 19 poniente, tapachula, chiapas, cp 30740,
mexico.

development protective broadly-acting vaccine widely
distributed human malaria parasite, plasmodium vivax, major step
towards malaria elimination. however, p. vivax vaccine remained elusive 
the scarcity pre-clinical models test protective efficacy support
further clinical trials. study, report development highly
protective csp-based p. vivax vaccine, virus-like particle (vlp) known rv21,
able provide 100% sterile protection stringent sporozoite challenge 
in rodent models malaria, igg2a antibodies associated with
protection absence detectable pvcsp-specific cell responses.
additionally, generated two novel transgenic rodent p. berghei parasite lines,
where p. berghei csp gene coding sequence replaced either
full-length p. vivax vk210 allelic vk247 csp additionally express
gfp-luciferase. efficacy rv21 surpassed viral-vectored vaccination using
chad63 mva. show first time chimeric vk210/247 antigen 
elicit high level cross-protection parasites expressing either csp
allele, provide accessible affordable models suitable support the
development p. vivax vaccines candidates. rv21 progressing gmp
production entered path towards clinical evaluation.

doi: 10.1038/srep46482 
pmcid: pmc5394459
pmid: 28417968  [indexed medline]

